% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • samsonisis samsonisis Oct 6, 2013 4:12 PM Flag

    Pink Sheets Daily - October 3, 2013

    Curis Propels Two Proprietary Drugs Forward In Plan To Retain Value

    Cancer drug developer Curis held its first R&D day Oct. 3, a sign its early pipeline is maturing. The company
    outlined development plans for two proprietary drugs, an IAP inhibitor and a PI3K/HDAC inhibitor, both in early
    clinical development. As for partnering those assets, CEO Passeri said the company is looking to retain more
    value for them than it did for Erivedge.

    Sentiment: Strong Buy

2.48-0.05(-1.98%)Sep 23 4:00 PMEDT